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Abstract 
 
Melanoma is a malignant tumour of melanocytes, which can spread to other organs of the 
body resulting in severe and/or lethal malignancies. Melanocytes are pigment producing 
cells found in deep layer of the epidermis and are originated from melanocytes stem cells 
through a cellular process called melanogenesis. Several genes, epigenetic and micro-
environmental factors are involved in this process via the regulation and maintenance of the 
balance between melanocytes stem cells proliferation and their differentiation into 
melanocytes. Dysregulation of this balance through gain or loss of function of key genes 
implicated in the control and regulation of cell cycle progression and/or differentiation results 
in melanoma initiation and progression. This review aims at providing a comprehensive 
overview about the origin of melanocytes, the oncogenic events involved in melanocytes 
stem cells transformation and the mechanisms implicated in the perpetuation of melanoma 
malignant phenotype. 
Keywords: Cancer stem cells, Malignant melanoma initiating cells, HAGE, ABCB5, 
MicroRNA, Chemoresistance, Melanocyte, RAS signalling. 
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Introduction 
Melanocytes journey began at gastrula stage of development where neural crest generate 
glial-melanocyte progenitors that commit to the production of melanoblasts [1, 2]. These 
cells generate later on melanocytes stem cells (MSCs), found in the hair follicle where they 
ensure the continuous generation of melanocytes, the cells responsible for melanin-pigment 
production throughout adult life. These cells possess stem cell-like properties associated 
with self-renewal and differentiation.  The process of transformation of MSCs results in the 
initiation of melanoma and/or its progression. In this regard, several factors involved in the 
early development and survival of MSCs such as MITF or EDNRB are overexpressed in 
melanoma and act as “survival” oncogenes [3-5]. Other causes of MSCs transformation 
involve genetic mutations targeting key genes implicated in cell cycle regulation, cell 
differentiation and signal transduction. Examples include mutations in tumour suppressor 
genes such CDKN2A and CDK4 and gain of function mutations affecting the RAS-RAF-
MAPK pathways responsible for nearly 75% (BRAF and NRAS mutations) of melanoma 
cases [Haluska FG et al. 2006] [6]. The implication of epigenetic factors in melanoma 
progression is reflected by the hypometylation or hypermethylation events affecting the 
expression of oncogenes and tumour suppressors, respectively. Up-regulation or down-
regulation of microRNAs expressions, which act as tumour suppressors or oncogenes 
through the regulation of target genes expression have also been shown to be implicated in 
melanoma progression [7]. More recently, the identification of malignant melanoma initiating 
cells expressing the chemo-resistant ATP-binding cassette (ABC) subfamily B member 5 
(ABCB5), responsible for reducing drug accumulation in ABCB5 positive tumour cells 
allowed better understanding of the chemotherapeutic refractoriness of advanced malignant 
melanoma [8]. These populations of cancer initiating cells express also the cancer testis 
antigen HAGE (DDX43) which plays an important role in their proliferation and survival 
through the activation of RAS-RAF-MAPK and RAS-Pi3K-AKT pathways [9]. This review 
attempts to highlight the important molecular and cellular events implicated in melanoma 
initiation and progression with regard to what is known about melanoma cancer initiating 
cells. 
From melanocytes to melanoma: the process of transformation 
Origin and regulation of melanocytes development 
Melanocytes are pigment producing cells found in the deep layer of the epidermis and are 
originated from the multipotent and highly migrating neural crest [1]. During embryonic 
development, neural crest found in the neural tube generates bipotential glial-melanocyte 
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progenitors which became lineage restricted and produce melanoblasts that originate 
melanocytes [2]. The commitment of glial-melanocyte progenitors into melanocytes involves 
Wnt signalling and takes place in the neural tube or after the cells migrating as suggested by 
Wnt1 and Wnt3a mice knockout studies [10]. In the opposite way, BMP signalling may 
functions through promoting the glial-melanocyte progenitors commitment to neural and glial 
progenitor cells [11]. Moreover, Wnt signalling has been reported to play a role in the 
terminal differentiation of melanoblasts indicating its key involvement in melanocytes 
development [12, 13]. Apart from Wnt signalling, several genes are important for 
melanocytes development through their involvement in the different developmental stages of 
melanogenesis. MITF, a gene which expression is induced by SOX10 and PAX3 and beta-
catenin, promotes melanocyte lineage specification and survival by activating the expression 
of pigment-producing genes such as DCT (dopachrome tautomerase) and tyrosinase and 
the anti-apoptotic gene BCL-2 [14] (Figure 1). The SLUG gene also induced by SOX10, 
initiates neural crest migration a step necessary for melanocyte development by repression 
of E-Cadherin and activation of Epithelial-mesenchymal transition essential to neural crest 
migration [15-17]. KIT a gene that belongs to type III receptor kinase is another important 
gene implicated in melanocyte development, migration and survival. Mutants animal models 
for this gene presented a fewer number of melanocytes probably due to a failure in 
melanocytes migration and enhanced apoptosis [18-21]. Other genes include endothelins, a 
group of vasoactive proteins that signal by binding to the G-coupled receptor EDNRA or 
EDNRB and play an essential role for survival and migration of melanoblast. Knock out 
models for the endothelin-B recptor (EDNRB) or its ligand Endothelin-3 showed a dramatic 
decrease of melanocytes number [5]. Finally, once melanoblasts arise, they migrate along 
the dorsolateral pathway between the dermatome and the epidermis toward the ventral 
midline and further invade the overlying epidermis, where they proliferate and migrate 
extensively to distribute the entire epidermis toward newly developing hair Follicles. In the 
follicles, melanoblasts are segregated into melanocytes and MSCs. The melanocytes 
contribute to the initial wave of melanogenesis while MSCs migrate in the lower permanent 
portion of the hair follicle and constitute the MC system in subsequent hair cycles [22, 23]. In 
conclusion, melanogenesis is a highly regulated spatio-temporal event which involves a 
pleiade of developmental factors that leads to the generation of melanocytes found later on 
in the epidermis skin and other tissues and organ of adult organism. 
 
Molecular pathogenesis and progression of melanoma 
 
Common genetic mutations associated with melanoma 
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In human skin, melanocytes reside in the basal layer of interfollicular epidermis and are 
thought to arise from MSCs in the hair follicle [24]. Several genes and pathways involved in 
the regulation of melanocyte proliferation and differentiation are subverted leading to an 
overproliferation of this population of cells resulting in melanoma. For instance, MITF, a 
molecule which promotes melanocyte lineage specification and survival is found 
overexpressed in many melanoma and has recently been characterised as a ‘lineage 
survival’ oncogene in melanoma [5]. EDNRB, an essential molecule involved in the 
developmental survival and migration of MSCs, is also found overexpressed in several 
human melanoma cell lines and EDNRB-specific antagonist inhibition led to the inhibition of 
the proliferation and the induction of melanoma cells differentiation [3, 4]. However, most of 
the causes associated with the dysregulation of melanocyte proliferation and differentiation 
are linked mainly to genetic factors and UV irradiation [25]. Nearly 60% and 15% of 
melanomas implicate somatic mutations that overactivate BRAF and NRAS genes, 
respectively [26, 27]. Other mutations, affect tumour suppressor genes such as CDKN2A 
and CDK4, and genes implicated in DNA repair machinery (Figure 2) [28]. 
 
BRAF a serine/threonine-protein kinase, is a component of the RAS–RAF–MAPK (mitogen-
activated protein kinase) signalling cascade, which is activated by many external stimuli, 
including growth-factor binding to receptor tyrosine kinases and G-protein-coupled receptors. 
Activation of this pathway results in the phosphorylation of MAPKs, which phosphorylate and 
regulate the activities of substrates such as transcription factors, cytoskeletal components 
and other kinases, involved in the regulation of cell survival, proliferation, differentiation and 
motility (Figure 2) [35]. Several studies have implicated BRAF in the molecular pathogenesis 
of melanoma most commonly through its mutant form BRAFV600E. This mutation results in 
700-fold overactivation of BRAF kinase activity and consequently promotes the oncogenic 
activation of proliferative and survival signalling pathways in melanoma cells [29, 30]. The 
NRAS GTPase functions upstream RAF serine-threonine kinases (ARAF, BRAF, CRAF) and 
upon its activation binds RAF and facilitates RAF induction and initiation of a kinase cascade 
that signals to the dual specificity kinases, MAPK/ERK kinases 1 and 2 (MEK1/2),and 
subsequently to ERKs 1 and 2. In a similar fashion, mutations of NRAS gene result in 
constitutive activation of downstream signalling pathways involving RAF serine-threonine 
kinases and leading to overproliferation and survival of melanoma cells (Figure 2) [31, 32]. 
Finally, other mutations of the MAPK pathways have been recently identified. MAP3K5 and 
MAP3K9 have been found to be mutated in 24% of melanoma cell lines while MAP2K1 and 
MAP2K2 where mutated in 8% of the melanoma cell lines analysed [33-35]. 
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Beside the implication of the RAS-RAF-MAPK pathways in melanoma pathogenesis and 
progression, mutations in tumour suppressor genes have been also reported in the literature. 
The CDKN2A locus encodes several spliced transcript variants and two of them encode the 
proteins INK4a and ARF both known to function as CDK4 inhibitors (Figure 2) [28]. ARF acts 
as a stabiliser of p53 through its interaction and sequestration of MDM2, a protein involved in 
the degradation of p53 and therefore enhancing p53-dependent transactivation and 
apoptosis. INK4a protein directly inhibits the cyclin D-dependent kinases CDK4 and CDK6 
responsible for the Retinoblastoma protein (pRb) phosphorylation and functional inactivation 
at G1-S phase of cell cycle progression. Rb phosphorylation by the CDKs prevents its 
interaction with the pro-proliferation factors E2Fs. Therefore, the loss of the CDKN2A locus 
in melanoma contributes to overproliferation of melanoma cells due to the absence of 
counterbalancing mechanisms involving ARF and INK4a [28]. Although, mutations in p53 
gene are rare event in melanoma, ARF frequent loss in melanoma suggests its important 
role in melanoma development [36]. Finally, patients with xeroderma pigmentosum (XP), a 
rare autosomal-recessive disease of mutated DNA repair genes that confer hypersensitivity 
to ultraviolet light, suggest that DNA repair is involved in the aetiology of melanoma and in 
melanoma progression. The common defect of XP affects the nucleotide excision repair 
(NER) enzymes (endonucleases and DNA polymerases) which if mutated lead to mutations 
in tumour suppressor genes such as TP53 or proto-oncogenes resulting in the development 
of melanoma [37-39]. 
In conclusion, further understanding of the correlation between the loss of functions of these 
genes and melanoma progression will greatly contribute to the effort of developing efficient 
drug based therapies 
MicroRNAs regulation of melanoma progression 
 
The involvement of microRNAs (miRNAs or miRs) in the epigenetic regulation of melanoma 
progression has been well described in the literature. In this chapter, a brief overview with 
examples of their role and importance in melanoma pathogenesis is provided. MicroRNAs 
have been shown to regulate the expression of a variety of tumour suppressor genes and 
oncogenes associated with melanoma initiation, progression and invasion [40, 41]. In many 
cases, the level of expression of miRNAs in melanoma cells is associated with their 
functions as tumour suppressors or oncogenes. Several miRs, including miR-137, miR-
221/222 and miR-182, have been found to be involved in melanoma progression by 
regulating key genes such as c-KIT, MITF, FOXO3, ITGB3 and CCND1 [40]. For example 
Mir-221/222 expression is upregulated in melanoma and correlates with an increased 
proliferation and activation of melanoma invasion/migration along with anchorage 
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independent growth. Mir-221/222 functions by down-regulating the expression of Kit and 
CDKN1B resulting in overproliferation and decreased differentiation of melanoma cells [42]. 
Mir-214 expression promotes melanoma cells invasion and motility by down-regulating the 
expression of the integrins member ITGA3 and the transcription factor TFAP2C [42]. In 
contrast, many microRNAs including miR-211, Let-7a, Let-7b, miR-193b and miR-205 
function as tumour suppressors when over-expressed in melanoma cell lines. MiR-211 
prevents melanoma progression by down-regulating the expression of BRN2, TGFBR2, 
NFAT5 and DPP4 [44, 45]. Let-7a and Let-7b regulate cell cycle progression by down-
regulating the expression of ITGB3 and the cyclins proteins CCNA, CCND1, CCND3 and 
CDK4, respectively [46, 47]. MiR-193b also down-regulated the expression of CCND1 in 
over-expression experiments while miR-205 down-regulated the expression of proliferation 
factors E2F1 and E2F5 [48, 49]. Finally, microRNAs are expressed at different stages of 
melanoma progression and understanding their functions will probably shed new light about 
the mechanisms that perpetuate the malignant phenotype and will open up the possibility to 
use miRNAs as diagnostic and prognostic markers as well as potential therapeutic targets 
for many malignancies. 
 
Malignant melanoma initiating cells (MMICs) 
 
In the skin, normal adult stem cells referred to as MSCs, form the cellular basis for skin 
homeostasis, maintenance, and repair [24]. These cells reside within a specialised stem cell 
niche called the bulge, located in the lower permanent portion of the hair follicle known as 
the outer root sheath [24, 50, 51].These melanocyte stem cells have the ability to replicate 
themselves through self-renewal, and to give rise to progenitor or transiently amplifying cells 
which further differentiate into melanin-producing melanocytes, that migrate to the base of 
the hair follicle (hair bulb) and provide pigment for the growing hair matrix (Figure 3) [51]. 
The existence of melanocyte stem cells and their role in self maintenance and generation of 
melanin-producing cells was demonstrated using melanocyte-tagged transgenic mice [52-
54]. These studies have shown that the hair greying observed in these mice, is due to 
incomplete melanocyte stem cell maintenance and identify Pax3, Bcl2 and Mitf as key 
molecules that help regulate the balance between MSC maintenance and differentiation 
(Figure 1) [55]. In MSCs, the expression of the transcription factor Pax3 and Dct were found 
up-regulated while the expression of Mitf and another important player Sox10 were found 
down-regulated providing to melanocyte stem cells a Dct+, Pax3
+
, Mitf
−
, Sox10
−
 molecular 
signature. Thus, this phenotype can maintain an undifferentiated state and promotes 
quiescence of these lineage-restricted stem cells [23]. More recently, Cheli and colleagues 
[56] demonstrated further the important role played by Mitf in promoting the differentiation of 
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MSCs. They showed that upon mitf depletion in melanoma cells, the levels of expression of 
Oct4 and Nanog (two key factors implicated in MSC maintenance) were upregulated, 
suggesting that oct4 and nanog genes might be direct transcriptional targets of Mitf. 
Furthermore, the authors reported in the same study an increase of the CDK inhibitor p27 
expression which correlated with the exacerbation of the tumourigenic properties of the 
melanoma cells. Another important player is Notch signalling which has been shown to 
promote the maintenance of melanocyte stem cells. Conditional ablation of Notch signalling 
in the melanocyte lineage led to a severe defect in hair pigmentation. Notch signalling 
through its downstream target HES1 prevented the elimination of MSCs by apoptosis [57]. In 
the other hand, elevated levels of Wnt signaling molecules, including activated β-catenin, 
antagonise the regulatory balance between PAX3, SOX10, and MITF towards terminal 
differentiation (Figure 1) [58-60]. Finally,  the POU domain transcription factor Brn-2 (N-Oct3, 
POU3F2), expressed  in the postnatal hair follicle melanocytes has been shown to be highly 
expressed  in melanomas, suggesting that Brn-2 may function as positive regulator of 
melanoma survival/proliferation. Brn-2 expression is up-regulated by both MAP kinase and 
-catenin signalling and may play a role in the downregulation of Mitf expression and in 
promoting cell invasion in vitro [61, 62]. 
Several studies have shown the importance of micro-environment in the regulation and 
maintenance of melanocyte stem cells. For instance, keratinocytes in close proximity to 
melanocyte stem cells, in the bulge in the outer root sheath, have been shown to regulate 
melanocyte stem cell fate by inducing SCF/c-KIT signalling through continuous secretion of 
Stem Cell Factor (SCF) [63].  Other studies have shown, the involvement of keratinocyte-
and/or fibroblast-secreted growth factors in recreating malignant melanoma environment that 
promotes the switching of cadherin subtypes and the decoupling of melanoma cells from the 
basement membrane, thereby accelerating melanoma cell proliferation and progression [64-
66]. During melanoma development, innate and adaptive immune cells are recruited in the 
vicinity of the tumour where they play a critical role in inducing angiogenesis, a critical 
process for the growth, invasion and metastasis of melanoma. For instance, macrophages 
induce angiogenesis by releasing granule-storing proteins that directly affects the 
bioavailability of angiogenic molecules such as the growth factor bFGF (FGF2) and 
interleukin-8 (IL-8) [67]. Mast cells which arrive first to the site of proliferation in response to 
tumour-originated stem cell factor (SCF) and growth factors, release vesicle-stored VEGF 
(vascular endothelial growth factor) [68], several serine proteases including chymase and 
tryptase [69] and matrix metalloproteinase-9 (MMP-9) [68, 70]. These molecules play an 
important role in tumour-associated vasculature. The switch to metastatic melanoma is an 
important process in melanoma progression and has been associated with the loss of 
expression of the transcription factor AP-2 which regulates the expression of VEGF, MMP-
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2 (matrix metalloproteinase-2), c-KIT, MCAM and the receptors PAR-1 (protease-activated 
receptor-1) and PAFR (platelet-activating factor receptor) [71]. 
Oncogenic events mediated by genetic mutations or epigenetic factors affecting key 
molecules such as MITF, SLUG, PAX3 and/or TWIST, involved in melanoma stem cells, 
quiescence, self-renewal and differentiation result in the transformation of normal 
melanocyte stem cells into populations of cancer cells with inherited properties of self-
renewal and differentiation [5, 58, 72, 73]. The involvement of the zinc finger protein SNAI1 
and TWIST in melanoma metastasis through a cellular process called epithelial-
mesenchymal transition (EMT) has been reported in the literature (Figure 4) [74, 75]. EMT is 
characterised by the expression of mesenchymal molecules such as fibronectin, vimentin, 
and metalloproteinases and inhibition of E-cadherin. In melanoma, this event has been 
associated with the constitutive hyperactivation of survival/antiapoptotic pathways such as 
the MAPK, NF-κB, and PI3K/AKT which regulate the expression of genes targeting the 
initiation of the metastatic cascade and involving SNAI1 and TWIST. Moreover, the zinc-
finger transcription factor SLUG which belongs to the SNAIL superfamily has been shown to 
function as a melanocyte-specific factor required for the strong metastatic propensity of 
melanoma [76].  SLUG pro-EMT function has been shown to be regulated by AKT and the 
secreted matricellular protein SPARC (also known as osteonectin) [77]. In conclusion, EMT 
involvement in melanoma metastasis appears to involve constitutive hyperactivation of RAS-
RAF-MAPK and RAS-Pi3K-AKT pathways. 
Cancer stem cells (CSCs) are thought to be implicated in melanoma tumour initiation, 
progression, chemoresistance and recurrence in human malignant melanoma [78-82]. 
Corresponding to various data, CSCs represent from 1 to 25% of total melanoma cell 
populations [62] In this regard; Fang and colleagues [78] were able to isolate melanoma 
populations with stem cell-like properties. Using sphere-forming assays, they were able to 
show that these subpopulations of human melanoma cells are able of self-renewal and to 
differentiate into multiple cell lineages. Xenotransplantation of these populations into 
immunodeficient mice, showed a higher tumourigenicity when compared with their adherent 
counterparts [78]. 
 
 More recently, Schatton and colleagues [8] isolated from human melanoma patients tissue, 
populations of malignant melanoma-initiating cells (MMICs) expressing the ATP-binding 
cassette (ABC) subfamily B member 5 (ABCB5). These populations of cells are highly 
tumourigenic when xenotransplanted in human to mouse experiments. They have been 
shown to possess the property of self-renewal and are able to differentiate into ABCB5 
positive and negative progeny. The expression of the ABCB5 molecule by MMICs may 
confer chemo-resistance responsible for recurrence and melanoma progression. High-
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expression levels of ABC drug efflux transporters reduced drug accumulation in ABCB5 
positive tumour cells which may explain the chemotherapeutic refractoriness of advanced 
malignant melanoma [83]. Finally, systemic administration of a monoclonal antibody directed 
to ABCB5, shown to be capable of inducing antibody-dependent cell-mediated cytotoxicity in 
ABCB5+ MMIC, exerted tumour-inhibitory effects further demonstrating the importance of 
ABCB5+ MMICs in melanoma initiation, progression and chemo-resistance [8]. Prior to these 
studies, several papers reported the presence of cancer stem cells populations in melanoma. 
The authors used markers such as CD20 (B-lymphocyte antigen CD20), CD133 (prominin-1) 
and ABCG2 (ATP-binding cassette sub-family G member 2) to isolate those populations [84, 
85]. However, the use of CD133 and ABCG2 to isolate stem cell populations raised a big 
controversy about their status as markers of melanocytes stem cells. For instance, CD133 
expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon 
cancer cells initiate tumours [86]. ABCG2 is expressed by a smaller subpopulation, but it is 
not known if this population possess self-renewal capacity one of the important properties 
associated with stem cell populations [87]. In conclusion, better understanding of the 
molecular mechanisms responsible for melanocytes stem cells transformation will provide 
key information about melanoma initiation, progression and chemo-resistance and will allow 
specific targeting of these malignant cells.  
 
The helicase HAGE (DDX43), ABCB5
+
 MMICs and melanoma progression 
 
Stem and progenitor cell-associated proteins such us cancer testis antigens are encoded by 
genes that are normally expressed only in the human germ line and the trophoblast, but are 
also aberrantly expressed in melanoma and a variety of human malignancies [88, 89],  
The helicase antigen (HAGE), a non-X-linked cancer testis (CT) antigen of 648 amino acids 
was originally identified in a rhabdomyosarcoma cell line [90]. HAGE, also known as DDX43 
or CT13, belongs to the DEAD-box family of ATP-dependent RNA helicases characterized 
by the presence of nine conserved motifs grouped into two domains connected by a 
polylinker SAT region [91]. The Q motif, motifs I, II (also called the D-E-A-D-box as a single-
letter code for Asp-Glu-Ala-Asp), and III, together with motif IV, bind and hydrolyze ATP 
molecules. The remaining motifs (V, VI, Ia, and Ib) are thought to interact with the RNA 
substrate. It has been suggested that RNA helicases browse RNA molecules in a 
bidirectional fashion using the energy gained from ATP hydrolysis until they encounter 
ribonucleoprotein-RNA complexes [92].The DEAD-box RNA helicases are ubiquitous, highly 
conserved enzymes that participate in nearly all aspects of RNA metabolism [92-96].  Their 
role in tumour growth has been reported previously for some members of this family. For 
instance, p68 (DDX5), p72 (DDX17), and Cancer Associated Antigen (CAGE) (DDX53) have 
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been implicated in promoting cell proliferation and survival in cancer cell lines from different 
tissue origins [97-104]. Members including Cancer Associated Antigen (CAGE) and HAGE 
(DDX43) were found to be highly expressed in different cancer tissues and cancer cell lines, 
suggesting their role in tumorigenesis [98-104].  
Recently, our group has identified a role of HAGE (DDX43) in promoting the proliferation and 
survival of ABCB5+ Malignant melanoma initiating cells (ABCB5
+
 MMICs) [8]. The 
implication of HAGE in melanoma ABCB5+ MMICs-mediated initiation and progression was 
determined by investigating the expression of HAGE and ABCB5 using melanoma tissue 
from patients, which showed a co-expression of HAGE and ABCB5
+
 in malignant melanoma 
initiating cells. Moreover, HAGE and ABCB5 co-expression was not generalised to the whole 
tumour and was localised to specific “niches” within melanoma tissues (Figure 5). In vitro, 
melanoma cell lines (FM82 and FM55) expressing naturally HAGE (DDX43) co-expressed 
also ABCB5 and were able to form melanoma-spheres [9]. Upon withdrawal of mitogens, 
these cells differentiated into ABCB5
+
 and ABCB5
-
 progeny. HAGE Knock-down 
experiments affected the proliferation of ABCB5+ MMICs, both in vitro using melanoma cell 
lines and in vivo using the NOD/SCID tumour xenotransplantation assay. Interestingly, the 
helicase HAGE promoted the proliferation and survival of ABCB5
+
 MMICs through 
increasing the expression of NRAS, a molecule involved in melanoma progression through 
its function as an activator of RAF-MAPK and PI3K-AKT pathways [9, 106-108]. The 
helicase HAGE appears to promote RAS expression by enhancing NRAS m RNA unwinding, 
which then increases NRAS mRNA translation in tumour cells [9]. So far, we do not know if 
the helicase HAGE has other functions in tumour cells or if it plays a direct role in ABCB5+ 
MMICs-mediated chemo-resistance by promoting the RNA unwinding and expression of 
ABCB5 in MMICs. Furthermore, hypomethylation of HAGE promoter has previously been 
reported in the literature which raises the question whether HAGE expression is associated 
with a specific stage of melanoma progression and whether this expression correlates with 
the expression of ABCB5 [109, 110]. Finally, as HAGE being expressed only by tumour cells 
suggest that cancer therapies targeting HAGE helicase may have broad applications for 
treating ABCB5
+
 malignant melanoma. 
Concluding remarks  
Substantial advances have been made in our understanding of the molecular mechanisms 
implicated in melanoma initiation and progression and further dissection of these events will 
enable the development of efficient drug based therapies targeting key molecules involved in 
perpetuating this malignancy. This effort is already taking place with the development of 
drugs targeting the mutant form of BRAF ( BRAFV600E ) or in combination with MEK1 inhibitor 
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[111, 112]. It will also allow further development of melanoma stage-specific biomarkers that 
enable the diagnosis and prediction of clinical outcome of melanoma patients. For instance, 
microRNAs expression during melanoma expression could be used to differentiate between 
benign and malignant lesions with poor versus favourable outcome.  Finally, as melanoma 
cancer initiating cells appear to play an important role in melanoma initiation and chemo-
resistance, further investigations of the molecular mechanisms implicated in their regulation 
will also enable the development of drugs based therapy targeting the molecules involved in 
the chemotherapeutic refractoriness of advanced malignant melanoma. To this date, this 
remains an important challenge facing the clinical and basic scientific communities. 
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Figures legends 
Fig 1 Schematic representation of MITF related pathway. MITF expression is induced by 
SOX10, PAX3 and Wnt/-catenin pathways. The induction of MITF promoter by -catenin is 
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counteracted by NOTCH signalling. MITF induces the expression of genes coding for anti-
apoptotic (BCL-2) and melanin producing (DCT and Tyrosinase) molecules. 
Fig 2 Signalling pathways implicated in the regulation of proliferation, apoptosis and 
angiogenesis. Binding of a growth factor to receptor tyrosine kinase (RTK) activate RAS and 
PI3K. RAS activates a downstream signal involving BRAF-MEK1/2-ERK1/2 which promotes 
proliferation and prevents apoptosis through the up-regulation of cyclin D1, which controls 
G1-S transition. AKT also stimulates proliferation by upregulating cyclin D1 and inhibition of 
p21, p27, which prevents G1/S transition. AKT-mediated inhibition of GSK-3 suppresses 
apoptosis. AKT-mediated activation of mTOR promotes angiogenesis by activating the 
transcriptor factor HIF-1 and the vascular endothelial growth factor (VEGF). p16INK4A and 
p14ARF encoded by CDKN2 gene inhibit the cell cycle progression and induce apoptosis 
respectively, through preventing cyclin D1/CDK4/6 interactions and inhibiting p53 
degradation through MDM2. 
Fig 3 Melanocyte stem cells and cancer initiation. (A) melanocytes reside in the basal layer 
of interfollicular epidermis and are thought to arise from melanocyte stem cells in the hair 
follicle. (B) Somatic mutations in melanocyte stem cells result in their transformation and 
initiation of melanoma. These cancer stem cells are thought to be responsible for the cases 
of relapse and chemoresistance. 
Fig 4 Involvement of epithelial-mesenchymal transition (EMT) in melanoma progression. (A) 
During embryonic development (gastrulation and neural crest formation), epithelial cells lose 
their adherent junctions, their attachments to the membrane basement and their baso-apical 
polarity which result in the production of highly migrating cells with mesenchymal 
characteristics, necessary for embryogenesis. (B) In melanoma, carcinoma cells under the 
influence of EMT signals undergo EMT with the generation of highly invasive and metastatic 
mesenchymal cells that reach other organs, convert to carcinoma cells in a process called 
mesenchymal-epithelial transition (MET). 
Fig 5 HAGE (DDX43) and ABCB5 co-expression in patient malignant melanoma sample. 
ABCB5 have been shown to be expressed by malignant melanoma initiating cells. 
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